Cargando…

Selenium and the risk of cancer in BRCA1 carriers

Detalles Bibliográficos
Autores principales:	Lubinski, J, Jaworska, K, Durda, K, Jakubowska, A, Huzarski, T, Byrski, T, Stawicka, M, Gronwald, J, Górski, B, Wasowicz, W, Kilar, E, Szwiec, M, Surdyka, D, Marczyk, E, Sun, P, Narod, SA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108170/ http://dx.doi.org/10.1186/1897-4287-9-S2-A5

Ejemplares similares

Selenium and genotypes as marker of risk in BRCA1 mutation carriers
por: Jaworska, K, et al.
Publicado: (2012)

Impact of BRCA1 mutation on survival after early onset breast cancer
por: Huzarski, T, et al.
Publicado: (2012)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

Prospective observation of breast/ovarian cancer risk in BRCA1 carriers depending on serum selenium level optimized with diet
por: Lubiński, J, et al.
Publicado: (2012)

Folic acid and cancer risk in BRCA1 carriers
por: Durda, Katarzyna, et al.
Publicado: (2012)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

Selenium (Se) and the risk of breast, ovarian and prostate cancers
por: Jaworska, Katarzyna, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Selenium (Se) and breast cancer risk
por: Jaworska - Bieniek, Katarzyna, et al.
Publicado: (2012)

Vitamins A, E and D and cancer risk in BRCA1 carriers
por: Kąklewski, K, et al.
Publicado: (2012)

Selenium and cancer risk in CHEK2 mutation carriers
por: Gupta, Satish, et al.
Publicado: (2012)

Selenium as diagnostic marker of cancers
por: Jaworska-Bieniek, Katarzyna, et al.
Publicado: (2015)

Pathological complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
por: Byrski, Tomasz, et al.
Publicado: (2015)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2016: Szczecin, Poland. 14-15 September 2016
por: Cybulski, C., et al.
Publicado: (2017)

A Lowering of Breast and Ovarian Cancer Risk in Women with a BRCA1 Mutation by Selenium Supplementation of Diet
por: Huzarski, Tomasz, et al.
Publicado: (2006)

The risk of breast cancer in women with a CHEK2 mutation
por: Cybulski, Cezary, et al.
Publicado: (2012)

CHEK2 mutations as markers for high risk of breast cancer
por: Cybulski, Cezary, et al.
Publicado: (2012)

Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism
por: Jakubowska, Anna, et al.
Publicado: (2008)

Zinc and breast cancer risk
por: Kaczmarek, Katarzyna, et al.
Publicado: (2012)

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer
por: Łukomska, Alicja, et al.
Publicado: (2021)

Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband
por: Gronwald, J, et al.
Publicado: (2009)

Serum concentration of iron as predictor of cancer risk among BRCA1 mutation carriers
por: Sukiennicki, Grzegorz, et al.
Publicado: (2012)

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor
por: Ogrodniczak, Alicja, et al.
Publicado: (2022)

Serum concentration of selected macro- and microelements and their correlation with the risk of breast and ovarian cancer among BRCA1 mutation carriers
por: Muszyńska, Magdalena, et al.
Publicado: (2012)

Selenium and the risk of cancer of the lung and larynx. A case-control study from a region with low selenium
por: Jaworska, Katrzyna, et al.
Publicado: (2012)

Identification of new genes associated with breast and ovarian cancer risk. Advances of BCAC, CIMBA and OCAC
por: Jakubowska, A, et al.
Publicado: (2011)

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East Poland
por: Kluz, Tomasz, et al.
Publicado: (2018)

Copper as diagnostic marker of cancers
por: Muszyńska, Magdalena, et al.
Publicado: (2015)

Magnesium as a diagnostic marker of cancer
por: Marciniak, Wojciech, et al.
Publicado: (2015)

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
por: Byrski, Tomasz, et al.
Publicado: (2012)

Zinc as diagnostic marker of cancers
por: Kaczmarek, Katarzyna, et al.
Publicado: (2015)

Iron as diagnostic marker of cancer
por: Sukiennicki, Grzegorz, et al.
Publicado: (2015)

Identification of patients at high risk of negative psychological consequences associated with BRCA1 mutation
por: Ertmański, S, et al.
Publicado: (2012)

Serum Selenium Level Predicts 10-Year Survival after Breast Cancer
por: Szwiec, Marek, et al.
Publicado: (2021)

Rapid test for detection of high risk of breast cancer
por: Durda, K, et al.
Publicado: (2012)

Folic acid and breast cancer risk
por: Durda, Katarzyna, et al.
Publicado: (2012)

Clinical Genetic Services for Familial Breast Cancer in Poland
por: Gronwald, J., et al.
Publicado: (1999)

The influence of selenium concentration and variations in selenoprotein genes on the CHEK2-dependent cancers
por: Gupta, Satish, et al.
Publicado: (2015)

Serum selenium level and cancer risk: a nested case-control study
por: Narod, Steven A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1lqe8ga5988v98vcj474vgumqj